What is 4P Pharma?
Established in 2014, 4P Pharma operates at the intersection of academic research and commercial drug development. By functioning as a specialized R&D partner, the company bridges the gap between early-stage discovery and clinical application. Their operational framework is defined by a patient-centric approach, utilizing advanced AI-driven technologies and strategic alliances with academic institutions to de-risk the drug development lifecycle. This model allows 4P Pharma to maintain a lean, agile structure while managing a robust portfolio of therapeutic assets aimed at serious, high-impact diseases.
How much funding has 4P Pharma raised?
4P Pharma has raised a total of $16.1M across 1 funding round:
Other Financing Round
$16.1M
Other Financing Round (2024): $16.1M, investors not publicly disclosed
Key Investors in 4P Pharma
Undisclosed Investors
Undisclosed Investors
Undisclosed Investors
What's next for 4P Pharma?
With this recent infusion of capital, 4P Pharma is poised to scale its R&D engine and deepen its integration with AI-tech partners to streamline preclinical development. The strategic focus will likely shift toward expanding its therapeutic pipeline and enhancing market access capabilities. By leveraging its co-risk model, the company aims to solidify its reputation as a premier partner for life science investors and academic entities, ultimately accelerating the delivery of novel therapies to patients globally. Future growth will be contingent on the successful advancement of its current clinical candidates and the continued optimization of its collaborative development ecosystem.
See full 4P Pharma company page
